Literature DB >> 16917867

The role of surgery in treatment of stage IV melanoma.

Shawn E Young1, Steve R Martinez, Richard Essner.   

Abstract

The prognosis for patients with melanoma has not improved over the last 30 years. So far, almost without exception, clinical trials conducted with single or multiple agent chemotherapy, biological therapy (interferon-alpha, interleukin-2), and biochemotherapy have failed to demonstrate consistent survival benefit. Without effective alternate treatments, surgery must be considered the primary treatment of melanoma, independent of disease stage. Although surgery is clearly favored as the treatment of localized melanoma, consensus opinion and clinician preference become divided once melanoma progresses beyond its primary site. Many physicians will adopt an attitude of resignation and hesitancy when treating metastatic melanoma. As a result, patients with advanced disease are often treated with medications that produce little survival or palliative benefit at the expense of significant toxicity. Numerous studies have demonstrated clear and durable survival advantages for patients undergoing complete resection of metastatic melanoma. Further, surgical resection can produce an immediate decrease in tumor burden with minimal morbidity and mortality at a reasonable cost. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16917867     DOI: 10.1002/jso.20303

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  17 in total

1.  Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma.

Authors:  Shun-Da Du; Yi-Lei Mao; Shao-Hua Li; Xin-Ting Sang; Xin Lu; Yi-Yao Xu; Hai-Feng Xu; Lin Zhao; Chun-Mei Bai; Shou-Xian Zhong; Jie-Fu Huang
Journal:  World J Hepatol       Date:  2012-11-27

2.  A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Authors:  Jeffrey A Sosman; James Moon; Ralph J Tuthill; James A Warneke; John T Vetto; Bruce G Redman; P Y Liu; Joseph M Unger; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

3.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.

Authors:  Yan Xing; Yulia Bronstein; Merrick I Ross; Robert L Askew; Jeffrey E Lee; Jeffrey E Gershenwald; Richard Royal; Janice N Cormier
Journal:  J Natl Cancer Inst       Date:  2010-11-16       Impact factor: 13.506

Review 4.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

5.  Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.

Authors:  Oliver G Goldstein; Laela M Hajiaghamohseni; Shereen Amria; Kumaran Sundaram; Sakamuri V Reddy; Azizul Haque
Journal:  Cancer Immunol Immunother       Date:  2008-03-15       Impact factor: 6.968

Review 6.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

7.  Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera.

Authors:  Lynn T Dengel; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2009-11-01       Impact factor: 3.454

8.  Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.

Authors:  Seagal Teitz-Tennenbaum; Qiao Li; Mary A Davis; Kari Wilder-Romans; Janet Hoff; Mu Li; Alfred E Chang
Journal:  J Immunother       Date:  2009 Jul-Aug       Impact factor: 4.456

9.  Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients.

Authors:  Francesca Tauceri; Gianni Mura; Mauro Roseano; Massimo Framarini; Laura Ridolfi; Giorgio M Verdecchia
Journal:  Langenbecks Arch Surg       Date:  2008-03-04       Impact factor: 3.445

10.  Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV.

Authors:  Bożena Cybulska-Stopa; Marta Skoczek; Marek Ziobro; Tomasz Switaj; Sławomir Falkowski; Tadeusz Morysiński; Marcin Hetnał; Ida Cedrych; Piotr Rutkowski
Journal:  Contemp Oncol (Pozn)       Date:  2013-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.